logo
welcome
Benzinga

Benzinga

Cigna Not Pursuing Humana Merger, Stock Soars

Benzinga
Summary
Nutrition label

76% Informative

Cigna confirms it is not pursuing a combination with Humana Inc. ( NYSE :HUM) The company reaffirm its projected full-year 2024 consolidated adjusted EPS outlook of at least $28.40 per share and growth of 10% in 2025 .

Last month , a Bloomberg report noted that CignA had reinitiated discussions to merge with.

Humana .

VR Score

71

Informative language

69

Neutral language

4

Article tone

formal

Language

English

Language complexity

60

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

External references

9

https://www.benzinga.com/markets/equities/23/11/36007194/whats-going-on-with-healthcare-insurance-giant-cigna-stock-today?utm_campaign=partner_feed&utm_source=yahooFinance&utm_medium=partner_feed&utm_content=site&nid=41877573https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9spja3yaad2&utm_source=yahoohttps://www.benzinga.com/news/large-cap/24/10/41256923/cvs-unitedhealth-request-ftc-chair-recusal-amid-ongoing-pharmacy-benefit-managers-lawsuit?utm_campaign=partner_feed&utm_source=yahooFinance&utm_medium=partner_feed&utm_content=site&nid=41877573https://www.benzinga.comhttps://www.benzinga.com/news/large-cap/24/10/41429974/cigna-and-humana-revive-early-merger-talks-after-year-long-pause-as-medicare-cost-pressure-looms?utm_campaign=partner_feed&utm_source=yahooFinance&utm_medium=partner_feed&utm_content=site&nid=41877573https://www.benzinga.com/general/health-care/24/11/41877573/cigna-not-pursuing-humana-merger-stock-soarshttps://www.benzinga.com/general/biotech/24/11/41876225/ars-pharmaceuticals-inks-licensing-pact-for-neffy-allergic-reaction-treatment-analyst-sees-further-stock-upside-despite-200-surge-in-2024?utm_campaign=partner_feed&utm_source=yahooFinance&utm_medium=partner_feed&utm_content=site&nid=41877573https://www.benzinga.com/news/earnings/24/10/41656437/cignas-q3-profit-beats-street-on-strong-demand-for-pharmacy-benefit-managements-specialty-drugs-new?utm_campaign=partner_feed&utm_source=yahooFinance&utm_medium=partner_feed&utm_content=site&nid=41877573https://www.benzinga.com/pressreleases/24/11/n41875788/the-cigna-group-affirming-its-capital-priorities?utm_campaign=partner_feed&utm_source=yahooFinance&utm_medium=partner_feed&utm_content=site&nid=41877573

Source diversity

1

Affiliate links

no affiliate links